

# Per S StÃ¼l

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8576924/publications.pdf>

Version: 2024-02-01

86  
papers

7,197  
citations

136950

32  
h-index

58581

82  
g-index

86  
all docs

86  
docs citations

86  
times ranked

8395  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucagon and Liver Fat are Downregulated in Response to Very Low-calorie Diet in Patients with Obesity and Type-2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 55-60.	1.2	2
2	Liver transplantation in patients with post-hepatectomy liver failure – A Northern European multicenter cohort study. <i>Hpb</i> , 2022, 24, 1138-1144.	0.3	4
3	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	7.0	32
4	The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study. <i>United European Gastroenterology Journal</i> , 2022, 10, 465-476.	3.8	15
5	Variation in textural parameters of hepatic lesions during contrast medium injection. <i>Acta Radiologica</i> , 2021, 62, 1317-1323.	1.1	1
6	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 297-297.	1.6	4
7	Morbidity, risk of cancer and mortality in 3645 <i>HTF</i> mutations carriers. <i>Liver International</i> , 2021, 41, 545-553.	3.9	11
8	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 437-442.	1.5	4
9	A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 1021-1035.	4.3	23
10	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. <i>JHEP Reports</i> , 2021, 3, 100218.	4.9	26
11	Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial. <i>JHEP Reports</i> , 2021, 3, 100256.	4.9	87
12	Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1431-1442.	2.0	20
13	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. <i>Cancers</i> , 2021, 13, 4334.	3.7	20
14	Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 18025.	3.3	20
15	Reply to: –Reduced steatosis and weight as a result of specific diets or the dietitian themselves–. <i>JHEP Reports</i> , 2021, 3, 100366.	4.9	0
16	A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1420-1426.	1.6	4
17	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1592-1599.e8.	4.4	21
18	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Transient liver elastography in normal pregnancy – a longitudinal cohort study. Scandinavian Journal of Gastroenterology, 2019, 54, 761-765.	1.5	26
20	Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scandinavian Journal of Gastroenterology, 2019, 54, 905-912.	1.5	17
21	SAT-416-Transient elastography in normal pregnancies: A prospective cohort study. Journal of Hepatology, 2019, 70, e817-e818.	3.7	0
22	Alcohol and drug use prior to liver transplantation: more common than expected in patients with non-alcoholic liver disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1146-1154.	1.5	3
23	Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. Frontiers in Immunology, 2019, 10, 1255.	4.8	58
24	Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver International, 2019, 39, 1098-1108.	3.9	59
25	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1148-1156.e4.	4.4	71
26	Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver International, 2019, 39, 197-204.	3.9	75
27	Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver International, 2018, 38, 2082-2090.	3.9	47
28	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatology Communications, 2018, 2, 48-57.	4.3	200
29	Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 104-110.	2.5	9
30	Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver International, 2018, 38, 885-894.	3.9	25
31	Reply to “Comment on “In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma” Molecular Pharmaceutics, 2018, 15, 336-340.	4.6	1
32	Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Gastroenterology Research and Practice, 2018, 2018, 1-7.	1.5	16
33	Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease. BMC Gastroenterology, 2018, 18, 78.	2.0	27
34	Triple Arterial Phase CT of the Liver with Radiation Dose Equivalent to That of Single Arterial Phase CT: Initial Experience. Radiology, 2018, 289, 111-118.	7.3	13
35	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology, 2017, 65, 1557-1565.	7.3	1,294
36	Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1461-1468.	4.4	37

#	ARTICLE	IF	CITATIONS
37	<i>In Vivo</i> Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. <i>Molecular Pharmaceutics</i> , 2017, 14, 448-458.	4.6	30
38	IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD – a pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1427-1434.	1.5	36
39	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 67, 1265-1273.	3.7	730
40	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	1.5	32
41	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	1.5	60
42	Reverse lectin ELISA for detecting fucosylated forms of $\alpha$ 1-acid glycoprotein associated with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0173897.	2.5	19
43	Bilateral muscle fiber and nerve influences by TNF-alpha in response to unilateral muscle overuse – studies on TNF receptor expressions. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 498.	1.9	5
44	Reply. <i>Hepatology</i> , 2016, 64, 310-311.	7.3	0
45	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , 2016, 36, 1688-1695.	3.9	54
46	Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. <i>Journal of Hepatology</i> , 2016, 65, 363-368.	3.7	68
47	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , 2016, 11, e0167776.	2.5	17
48	FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00171.	2.4	17
49	Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?. <i>Liver International</i> , 2015, 35, 1862-1871.	3.9	55
50	Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. <i>World Journal of Gastroenterology</i> , 2015, 21, 11077.	3.3	132
51	Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. <i>European Radiology</i> , 2015, 25, 3123-3132.	4.5	43
52	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. <i>Hepatology</i> , 2015, 61, 1547-1554.	7.3	1,683
53	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015, 11, 2553-2562.	2.4	13
54	Validation of a competitive ELISA assay for the quantification of human serum hepcidin. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 652-8.	1.2	12

#	ARTICLE	IF	CITATIONS
55	Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. <i>Human Molecular Genetics</i> , 2014, 23, 3883-3890.	2.9	50
56	Sorafenib prolongs liver regeneration after hepatic resection in rats. <i>Journal of Surgical Research</i> , 2013, 184, 847-854.	1.6	6
57	A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 230-236.	5.8	206
58	Iron-regulatory gene expression during liver regeneration. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 591-600.	1.5	9
59	Abnormal Mitochondria Organization and Oxidative Activity in the Palate Muscles of Long-Term Snorers with Obstructive Sleep Apnea. <i>Respiration</i> , 2012, 83, 407-417.	2.6	36
60	Effects on Contralateral Muscles after Unilateral Electrical Muscle Stimulation and Exercise. <i>PLoS ONE</i> , 2012, 7, e52230.	2.5	30
61	Alcohol consumption in patients with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2012, 18, 3105.	3.3	17
62	Attenuated liver fibrosis after bile duct ligation and defective hepatic stellate cell activation in neural cell adhesion molecule knockout mice. <i>Liver International</i> , 2011, 31, 630-641.	3.9	11
63	Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. <i>Apmis</i> , 2011, 119, 412-420.	2.0	32
64	Liver transplantation for erythropoietic protoporphyria in Europe. <i>Liver Transplantation</i> , 2011, 17, 1021-1026.	2.4	60
65	Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1118-1126.	1.5	12
66	Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. <i>Hepatology</i> , 2010, 51, 595-602.	7.3	643
67	DNA adducts in normal colonic mucosa from healthy controls and patients with colon polyps and colorectal carcinomas. <i>Mutagenesis</i> , 2010, 25, 499-504.	2.6	14
68	Liver transplantation of patients with cryptogenic cirrhosis: Clinical characteristics and outcome. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 60-69.	1.5	21
69	A novel mutation in the biliverdin reductase gene combined with liver cirrhosis results in hyperbilirubinaemia (green jaundice). <i>Liver International</i> , 2009, 29, 1116-1124.	3.9	29
70	Increased Mortality Risk in Patients With Phenotypic Hereditary Hemochromatosis But Not in Their First-Degree Relatives. <i>Gastroenterology</i> , 2009, 137, 1301-1309.	1.3	19
71	Regulatory effects of tumor necrosis factor-alpha and interleukin-6 on HAMP expression in iron loaded rat hepatocytes. <i>Journal of Hepatology</i> , 2006, 44, 544-551.	3.7	16
72	Uncoordinated Expression of Myosin Heavy Chains and Myosin-Binding Protein C Isoforms in Human Extraocular Muscles. , 2006, 47, 4188.		18

#	ARTICLE	IF	CITATIONS
73	Expression of iron regulatory genes in a rat model of hepatocellular carcinoma. Liver International, 2006, 26, 976-985.	3.9	38
74	Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology, 2003, 125, 1733-1741.	1.3	246
75	Structure and liver cell expression pattern of the HFE gene in the rat. Journal of Hepatology, 2003, 39, 308-314.	3.7	27
76	Ubiquinone, Oxidative Stress, and Liver Carcinogenesis. Modern Nutrition, 2000, , 317-329.	0.1	6
77	Effects of dietary iron overload on progression in chemical hepatocarcinogenesis. Liver International, 1999, 19, 326-334.	3.9	10
78	Quantitative determination of 8-hydroxy-2â€²-deoxyguanosine in human urine by isotope dilution mass spectrometry: normal levels in hemochromatosis. Free Radical Biology and Medicine, 1999, 26, 129-135.	2.9	46
79	Dietary iron overload inhibits carbon tetrachloride-induced promotion in chemical hepatocarcinogenesis: effects on cell proliferation, apoptosis, and antioxidation. Journal of Hepatology, 1999, 30, 689-698.	3.7	35
80	Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. Journal of Hepatology, 1998, 29, 819-825.	3.7	26
81	Studies on genotoxic effects of iron overload and alcohol in an animal model of hepatocarcinogenesis. Journal of Hepatology, 1997, 27, 562-571.	3.7	13
82	Hepatotoxicity induced by iron overload and alcohol. Journal of Hepatology, 1996, 25, 538-546.	3.7	52
83	The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis. Hepatology, 1995, 21, 521-528.	7.3	38
84	Iron as a Hepatotoxin. Digestive Diseases, 1995, 13, 205-222.	1.9	38
85	Iron increases ethanol toxicity in rat liver. Journal of Hepatology, 1993, 17, 108-115.	3.7	72
86	Liver cell damage and lysosomal iron storage in patients with idiopathic hemochromatosis. Journal of Hepatology, 1990, 11, 172-180.	3.7	41